Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

DKK 2016 | Chemotherapy-free management of indolent lymphoma

Wolfgang Hiddemann • 25 Feb 2016
DKK 2016
Non-Hodgkin Lymphoma Ibrutinib Idelalisib

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Wolfgang Hiddemann, MD, PhD, from the University of Munich, Munich, Germany, provides an overview of chemotherapy-free approaches in clinical development for the treatment of patients with indolent lymphoma. Promising approaches include the Bruton tyrosine kinase inhibitor, ibrutinib, and PI3K-delta inhibitor, idelalisib, in combinations with anti-CD20 monoclonal antibodies; Bcl-2 inhibitors; and PD-1 immune checkpoint inhibitors.
Institution website: http://www.klinikum.uni-muenchen.de/Medizinische-Klinik-und-Poliklinik-III/de/team/hiddemann_w/index.html

More from Wolfgang Hiddemann

3:08
ISAL 2023: looking forward to this year's meeting and insights into the program
Wolfgang Hiddemann • 16 Mar 2023
2:52
International Symposium on Acute Leukemias: key messages from the 2019 meeting
Wolfgang Hiddemann • 15 Mar 2019
1:04
Acute leukemia research at LMU Munich
Wolfgang Hiddemann • 14 Mar 2019
8:26
Challenging the norms for elderly AML treatment: clinical trials & intensive therapy
Alan Burnett et al. • 17 Feb 2018

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals